Peregrine Pharma (PPHM) Tops Q1 EPS by 6c, Beats on Revenues

Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $27.07 million versus the consensus estimate of $15.2 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c